<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29787616</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>12</Month>
        <Day>11</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>12</Month>
        <Day>16</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Electronic">1932-6203</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>13</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2018</Year>
            </PubDate>
          </JournalIssue>
          <Title>PloS one</Title>
          <ISOAbbreviation>PLoS One</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Efficacy and safety of saxagliptin in patients with type 2 diabetes: A systematic review and meta-analysis.</ArticleTitle>
        <Pagination>
          <StartPage>e0197321</StartPage>
          <MedlinePgn>e0197321</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="pii" ValidYN="Y">e0197321</ELocationID>
        <ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0197321</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE">To evaluate the comparative efficacy and safety of saxagliptin for type 2 diabetes (T2D).</AbstractText>
          <AbstractText Label="METHODS">A systematic search of PubMed, Embase, the Cochrane Library, Web of Science, ClinicalTrials.gov and two Chinese databases for randomized controlled trials (RCTs) comparing saxagliptin with placebo or active comparators was performed up to July 2017. A complementary search was done to cover literature until March 2018. For continuous data, estimates were pooled using inverse variance methodology to calculate weighted mean differences (WMDs). Dichotomous data were presented as Mantel-Haenzel risk ratios (RRs).</AbstractText>
          <AbstractText Label="RESULTS">Thirty-nine references of 30 RCTs involving 29,938 patients were analyzed. Compared with placebo, saxagliptin significantly reduced glycated hemoglobin (HbA1c, WMD -0.52%, 95% CI -0.60 to -0.44) and fasting plasma glucose (WMD -13.78 mg/dL, 95% CI -15.31 to -12.25), and increased the proportion of patients achieving HbA1c &lt;7% (RR 1.64, 95% CI 1.53 to 1.75). When combined with submaximal-dose metformin, saxagliptin significantly increased the proportion of patients achieving HbA1c &lt;7% compared with acarbose (RR 2.38, 95% CI 1.17 to 4.83) and uptitrated metformin (RR 1.30, 95% CI 1.04 to 1.63). Saxagliptin was similar to other DPP-4 inhibitors but inferior to liraglutide and dapagliflozin on glycemic control. Saxagliptin significantly decreased the incidences of overall adverse events compared with acarbose (RR 0.71, 95% CI 0.57 to 0.89) and liraglutide (RR 0.41, 95% CI 0.24 to 0.71) when added to metformin. Weight gain and hypoglycemia with saxagliptin was slightly but significantly higher than placebo and lower than sulfonylureas. Saxagliptin did not increase the risk of arthralgia, heart failure, pancreatitis and other adverse events.</AbstractText>
          <AbstractText Label="CONCLUSIONS">Generally, saxagliptin has similar efficacy compared with most oral antidiabetic drugs and may be more effective than acarbose, while having a better safety profile than both acarbose and sulfonylureas.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Men</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University Third Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Li</LastName>
            <ForeName>Xiao-Tong</ForeName>
            <Initials>XT</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University Third Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Tang</LastName>
            <ForeName>Hui-Lin</ForeName>
            <Initials>HL</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University Third Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhai</LastName>
            <ForeName>Suo-di</ForeName>
            <Initials>SD</Initials>
            <Identifier Source="ORCID">0000-0003-2220-359X</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacy, Peking University Third Hospital, Beijing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D017418">Meta-Analysis</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>05</Month>
          <Day>22</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>PLoS One</MedlineTA>
        <NlmUniqueID>101285081</NlmUniqueID>
        <ISSNLinking>1932-6203</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D004151">Dipeptides</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D054873">Dipeptidyl-Peptidase IV Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>9GB927LAJW</RegistryNumber>
          <NameOfSubstance UI="C502994">saxagliptin</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>PJY633525U</RegistryNumber>
          <NameOfSubstance UI="D000218">Adamantane</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000218" MajorTopicYN="N">Adamantane</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
          <QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D003924" MajorTopicYN="N">Diabetes Mellitus, Type 2</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004151" MajorTopicYN="N">Dipeptides</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054873" MajorTopicYN="N">Dipeptidyl-Peptidase IV Inhibitors</DescriptorName>
          <QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
      <CoiStatement>The authors have declared that no competing interests exist.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2017</Year>
          <Month>11</Month>
          <Day>15</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2018</Year>
          <Month>4</Month>
          <Day>29</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2018</Year>
          <Month>5</Month>
          <Day>23</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>12</Month>
          <Day>12</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29787616</ArticleId>
        <ArticleId IdType="pmc">PMC5963790</ArticleId>
        <ArticleId IdType="doi">10.1371/journal.pone.0197321</ArticleId>
        <ArticleId IdType="pii">PONE-D-17-40100</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Ogurtsova K, da Rocha Fernandes JD, Huang Y, Linnenkamp U, Guariguata L, Cho NH, et al.
IDF Diabetes Atlas: Global estimates for the prevalence of diabetes for 2015 and 2040. Diabetes Res Clin Pract. 2017;128:40–50. doi: 10.1016/j.diabres.2017.03.024 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabres.2017.03.024</ArticleId>
            <ArticleId IdType="pubmed">28437734</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang P, Zhang X, Brown J, Vistisen D, Sicree R, Shaw J, et al.
Global healthcare expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010;87(3):293–301. doi: 10.1016/j.diabres.2010.01.026 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabres.2010.01.026</ArticleId>
            <ArticleId IdType="pubmed">20171754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Thornberry NA, Gallwitz B. Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4). Best Pract Res Clin Endocrinol Metab. 2009;23(4):479–86. doi: 10.1016/j.beem.2009.03.004 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.beem.2009.03.004</ArticleId>
            <ArticleId IdType="pubmed">19748065</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696–705. doi: 10.1016/S0140-6736(06)69705-5 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(06)69705-5</ArticleId>
            <ArticleId IdType="pubmed">17098089</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al.
Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm—2016 executive summary. Endocr Pract. 2016;22(1):84–113. doi: 10.4158/EP151126.CS .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.4158/EP151126.CS</ArticleId>
            <ArticleId IdType="pubmed">26731084</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Golightly LK, Drayna CC, McDermott MT. Comparative clinical pharmacokinetics of dipeptidyl peptidase-4 inhibitors. Clin Pharmacokinet. 2012;51(8):501–14. doi: 10.2165/11632930-000000000-00000 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11632930-000000000-00000</ArticleId>
            <ArticleId IdType="pubmed">22686547</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li H, Yang L, Tou CK, Patel CG, Zhao J. Pharmacokinetic study of saxagliptin in healthy Chinese subjects. Clin Drug Investig. 2012;32(7):465–73. doi: 10.2165/11598760-000000000-00000 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2165/11598760-000000000-00000</ArticleId>
            <ArticleId IdType="pubmed">22668067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li R, Wang R, Li H, Sun S, Zou M, Cheng G. Short-term and long-term effects of dipeptidyl peptidase-4 inhibitors in type 2 diabetes mellitus patients with renal impairment: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev. 2016;32(6):460–9. doi: 10.1002/dmrr.2731 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.2731</ArticleId>
            <ArticleId IdType="pubmed">26433213</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim YG, Min SH, Hahn S, Oh TJ, Park KS, Cho YM. Efficacy and safety of the addition of a dipeptidyl peptidase-4 inhibitor to insulin therapy in patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2016;116:86–95. doi: 10.1016/j.diabres.2016.03.011 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabres.2016.03.011</ArticleId>
            <ArticleId IdType="pubmed">27321321</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Foroutan N, Muratov S, Levine M. Safety and efficacy of dipeptidyl peptidase-4 inhibitors vs sulfonylurea in metformin-based combination therapy for type 2 diabetes mellitus: Systematic review and meta-analysis. Clin Invest Med. 2016;39(2):E48–62. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27040861</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Elgendy IY, Mahmoud AN, Barakat AF, Elgendy AY, Saad M, Abuzaid A, et al.
Cardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials. Am J Cardiovasc Drugs. 2017;17(2):143–55. doi: 10.1007/s40256-016-0208-x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40256-016-0208-x</ArticleId>
            <ArticleId IdType="pubmed">27873238</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sjöstrand M, Wei C, Cook W, Johnsson K, Pollack PS, Stahre C, et al.
Assessment of Saxagliptin Efficacy: Meta-Analysis of 14 Phase 2 and 3 Clinical Trials. Diabetes Ther. 2017;8(3):587–99. doi: 10.1007/s13300-017-0261-8 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s13300-017-0261-8</ArticleId>
            <ArticleId IdType="pmc">PMC5446386</ArticleId>
            <ArticleId IdType="pubmed">28432619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Knobloch K, Yoon U, Vogt PM. Preferred reporting items for systematic reviews and meta-analyses (PRISMA) statement and publication bias. J Craniomaxillofac Surg. 2011;39(2):91–2. doi: 10.1016/j.jcms.2010.11.001 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jcms.2010.11.001</ArticleId>
            <ArticleId IdType="pubmed">21145753</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28(4):513–23. doi: 10.1185/03007995.2012.665046 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/03007995.2012.665046</ArticleId>
            <ArticleId IdType="pubmed">22313154</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Barnett AH, Charbonnel B, Li J, Donovan M, Fleming D, Iqbal N. Saxagliptin add-on therapy to insulin with or without metformin for type 2 diabetes mellitus: 52-week safety and efficacy. Clin Drug Investig. 2013;33(10):707–17. doi: 10.1007/s40261-013-0107-8 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s40261-013-0107-8</ArticleId>
            <ArticleId IdType="pubmed">23949898</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R. Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract. 2009;63(9):1395–406. doi: 10.1111/j.1742-1241.2009.02143.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-1241.2009.02143.x</ArticleId>
            <ArticleId IdType="pmc">PMC2779994</ArticleId>
            <ArticleId IdType="pubmed">19614786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chacra AR, Tan GH, Ravichandran S, List J, Chen R. Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks. Diab Vasc Dis Res. 2011;8(2):150–9. doi: 10.1177/1479164111404574 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1479164111404574</ArticleId>
            <ArticleId IdType="pubmed">21562067</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Y, Liu X, Li Q, Ma J, Lv X, Guo L, et al.
Saxagliptin add-on therapy in Chinese patients with type 2 diabetes inadequately controlled by insulin with or without metformin: Results from the SUPER study, a randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2018;20(4):1044–1049. doi: 10.1111/dom.13161 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.13161</ArticleId>
            <ArticleId IdType="pubmed">29144061</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al.
The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes care. 2009;32(9):1649–55. doi: 10.2337/dc08-1984 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc08-1984</ArticleId>
            <ArticleId IdType="pmc">PMC2732156</ArticleId>
            <ArticleId IdType="pubmed">19478198</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenstock J, Gross JL, Aguilar-Salinas C, Hissa M, Berglind N, Ravichandran S, et al.
Long-term 4-year safety of saxagliptin in drug-naive and metformin-treated patients with Type 2 diabetes. Diabet Med. 2013;30(12):1472–6. doi: 10.1111/dme.12267 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dme.12267</ArticleId>
            <ArticleId IdType="pubmed">23802840</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Dou J, Ma J, Liu J, Wang C, Johnsson E, Yao H, et al.
Efficacy and safety of saxagliptin in combination with metformin as initial therapy in Chinese patients with type 2 diabetes: Results from the START study, a multicentre, randomized, double-blind, active-controlled, phase 3 trial. Diabetes Obes Metab. 2018;20(3):590–598. doi: 10.1111/dom.13117 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.13117</ArticleId>
            <ArticleId IdType="pubmed">28926170</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Du J, Liang L, Fang H, Xu F, Li W, Shen L, et al.
Efficacy and safety of saxagliptin compared with acarbose in Chinese patients with type 2 diabetes mellitus uncontrolled on metformin monotherapy: Results of a Phase IV open-label randomized controlled study (the SMART study). Diabetes Obes Metab. 2017;19(11):1513–20. doi: 10.1111/dom.12942 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.12942</ArticleId>
            <ArticleId IdType="pubmed">28296055</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fonseca V, Zhu T, Karyekar C, Hirshberg B. Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab. 2012;14(4):365–71. doi: 10.1111/j.1463-1326.2011.01553.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2011.01553.x</ArticleId>
            <ArticleId IdType="pubmed">22192246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Frederich R, McNeill R, Berglind N, Fleming D, Chen R. The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetol Metab Syndr. 2012;4(1):36
doi: 10.1186/1758-5996-4-36 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-5996-4-36</ArticleId>
            <ArticleId IdType="pmc">PMC3541110</ArticleId>
            <ArticleId IdType="pubmed">22828124</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010;64(12):1619–31. doi: 10.1111/j.1742-1241.2010.02510.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-1241.2010.02510.x</ArticleId>
            <ArticleId IdType="pubmed">20846286</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Göke B, Gallwitz B, Eriksson JG, Hellqvist A, Gause-Nilsson I. Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial. Int J Clin Pract. 2013;67(4):307–16. .</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23638466</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hermans MP, Delibasi T, Farmer I, Lohm L, Maheux P, Piatti P, et al.
Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr Med Res Opin. 2012;28(10):1635–45. doi: 10.1185/03007995.2012.735646 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/03007995.2012.735646</ArticleId>
            <ArticleId IdType="pubmed">23020253</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hollander P, Li J, Allen E, Chen R; CV181-013 Investigators. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab. 2009;94(12):4810–9. doi: 10.1210/jc.2009-0550 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1210/jc.2009-0550</ArticleId>
            <ArticleId IdType="pubmed">19864452</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hollander PL, Li J, Frederich R, Allen E, Chen R; CV181013 Investigators. Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus. Diab Vasc Dis Res. 2011;8(2):125–35. doi: 10.1177/1479164111404575 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1479164111404575</ArticleId>
            <ArticleId IdType="pubmed">21562064</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009;11(6):611–22. doi: 10.1111/j.1463-1326.2009.01056.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2009.01056.x</ArticleId>
            <ArticleId IdType="pubmed">19515181</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011;13(6):567–76. doi: 10.1111/j.1463-1326.2011.01385.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2011.01385.x</ArticleId>
            <ArticleId IdType="pubmed">21342412</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kadowaki T, Muto S, Ouchi Y, Shimazaki R, Seino Y. Efficacy and safety of saxagliptin in combination with insulin in Japanese patients with type 2 diabetes mellitus: a 16-week double-blind randomized controlled trial with a 36-week open-label extension. Expert Opin Pharmacother. 2017. 
December;18(18):1903–1919. doi: 10.1080/14656566.2017.1379990 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1080/14656566.2017.1379990</ArticleId>
            <ArticleId IdType="pubmed">28901796</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kumar KP, Jain SM, Tou C, Schützer K-M. Saxagliptin as initial therapy in treatment-naive Indian adults with type 2 diabetes mellitus inadequately controlled with diet and exercise alone: a randomized, double-blind, placebo-controlled, phase IIIb clinical study. Int J Diab Dev Ctries. 2014;34(4):201–9.</Citation>
        </Reference>
        <Reference>
          <Citation>Li CJ, Liu XJ, Bai L, Yu Q, Zhang QM, Yu P, et al.
Efficacy and safety of vildagliptin, Saxagliptin or Sitagliptin as add-on therapy in Chinese patients with type 2 diabetes inadequately controlled with dual combination of traditional oral hypoglycemic agents. Diabetol Metab Syndr. 2014;6:69
doi: 10.1186/1758-5996-6-69 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1758-5996-6-69</ArticleId>
            <ArticleId IdType="pmc">PMC4050987</ArticleId>
            <ArticleId IdType="pubmed">24917890</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Li CJ, Yu Q, Yu P, Zhang QM, Ding M, Liu XJ, et al.
Efficacy and safety comparison of add-on therapy with liraglutide, saxagliptin and vildagliptin, all in combination with current conventional oral hypoglycemic agents therapy in poorly controlled Chinese type 2 diabetes. Exp Clin Endocrinol Diabetes. 2014;122(8):469–76. doi: 10.1055/s-0034-1374586 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1055/s-0034-1374586</ArticleId>
            <ArticleId IdType="pubmed">24838155</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lv C, Yu P, Zhou S, Li C, Lv L, Chen R. Efficacy and safety of saxagliptin combined metformin in newly diagnosed type 2 diabetes mellitus patients. Chin J Diab Mel. 2013;5:759–62.</Citation>
        </Reference>
        <Reference>
          <Citation>Matthaei S, Catrinoiu D, Celinski A, Ekholm E, Cook W, Hirshberg B, et al.
Randomized, Double-Blind Trial of Triple Therapy With Saxagliptin Add-on to Dapagliflozin Plus Metformin in Patients With Type 2 Diabetes. Diabetes care. 2015;38(11):2018–24. doi: 10.2337/dc15-0811 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc15-0811</ArticleId>
            <ArticleId IdType="pubmed">26324329</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Matthaei S, Aggarwal N, Garcia-Hernandez P, Iqbal N, Chen H, Johnsson E, et al.
One-year efficacy and safety of saxagliptin add-on in patients receiving dapagliflozin and metformin. Diabetes Obes Metab. 2016;18(11):1128–33. doi: 10.1111/dom.12741 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.12741</ArticleId>
            <ArticleId IdType="pubmed">27403645</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, et al.
A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 diabetes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Metab. 2014;16(5):443–50. doi: 10.1111/dom.12234 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.12234</ArticleId>
            <ArticleId IdType="pubmed">24205943</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowicki M, Rychlik I, Haller H, Warren ML, Suchower L, Gause-Nilsson I. Saxagliptin improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus and renal impairment. Diabetes Obes Metab. 2011;13(6):523–32. doi: 10.1111/j.1463-1326.2011.01382.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2011.01382.x</ArticleId>
            <ArticleId IdType="pubmed">21332627</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Nowicki M, Rychlik I, Haller H, Warren M, Suchower L, Gause-Nilsson I, et al.
Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study. Int J Clin Pract. 2011;65(12):1230–9. doi: 10.1111/j.1742-1241.2011.02812.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1742-1241.2011.02812.x</ArticleId>
            <ArticleId IdType="pubmed">21977965</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pan CY, Yang W, Tou C, Gause-Nilsson I, Zhao J. Efficacy and safety of saxagliptin in drug-naive Asian patients with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Metab Res Rev. 2012;28(3):268–75. doi: 10.1002/dmrr.1306 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.1306</ArticleId>
            <ArticleId IdType="pubmed">22081481</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenstock J, Sankoh S, List JF. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naive patients with type 2 diabetes. Diabetes Obes Metab. 2008;10(5):376–86. doi: 10.1111/j.1463-1326.2008.00876.x .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1463-1326.2008.00876.x</ArticleId>
            <ArticleId IdType="pubmed">18355324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenstock J, Aguilar-Salinas C, Klein E, Nepal S, List J, Chen R. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin. 2009;25(10):2401–11. doi: 10.1185/03007990903178735 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1185/03007990903178735</ArticleId>
            <ArticleId IdType="pubmed">19650754</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rosenstock J, Hansen L, Zee P, Li Y, Cook W, Hirshberg B, et al.
Dual add-on therapy in type 2 diabetes poorly controlled with metformin monotherapy: a randomized double-blind trial of saxagliptin plus dapagliflozin addition versus single addition of saxagliptin or dapagliflozin to metformin. Diabetes care. 2015;38(3):376–83. doi: 10.2337/dc14-1142 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc14-1142</ArticleId>
            <ArticleId IdType="pubmed">25352655</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010;26(7):540–9. doi: 10.1002/dmrr.1114 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.1114</ArticleId>
            <ArticleId IdType="pubmed">20824678</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Schernthaner G, Duran-Garcia S, Hanefeld M, Langslet G, Niskanen L, Ostgren CJ, et al.
Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION). Diabetes Obes Metab. 2015;17(7):630–8. doi: 10.1111/dom.12461 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.12461</ArticleId>
            <ArticleId IdType="pubmed">25761977</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al.
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317–26. doi: 10.1056/NEJMoa1307684 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1307684</ArticleId>
            <ArticleId IdType="pubmed">23992601</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>White JL, Buchanan P, Li J, Frederich R. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. BMC Endocr Disord. 2014;14:17
doi: 10.1186/1472-6823-14-17 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/1472-6823-14-17</ArticleId>
            <ArticleId IdType="pmc">PMC3946011</ArticleId>
            <ArticleId IdType="pubmed">24565221</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Xia C, Peng H, Zhang G. Clinical trial of saxagliptin combined metformin in newly diagnosed type 2 diabetes mellitus patients. Chinese Remedies &amp; Clinics. 2014;14(5):640–2.</Citation>
        </Reference>
        <Reference>
          <Citation>Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011;94(2):217–24. doi: 10.1016/j.diabres.2011.07.035 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.diabres.2011.07.035</ArticleId>
            <ArticleId IdType="pubmed">21871686</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cahn A, Raz I, Mosenzon O, Leibowitz G, Yanuv I, Rozenberg A, et al.
Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes care. 2016;39(8):1329–37. doi: 10.2337/dc15-2763 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.2337/dc15-2763</ArticleId>
            <ArticleId IdType="pubmed">27222508</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hirshberg B, Parker A, Edelberg H, Donovan M, Iqbal N. Safety of saxagliptin: events of special interest in 9156 patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2014;30(7):556–69. doi: 10.1002/dmrr.2502 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.2502</ArticleId>
            <ArticleId IdType="pubmed">24376173</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US food and drug administration. Safety Alerts for Human Medical Products: Diabetes Medications Containing Saxagliptin and Alogliptin: Drug Safety Communication—Risk of Heart Failure. 2015 [cited 2016 Aug 17]. https://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm494252</Citation>
        </Reference>
        <Reference>
          <Citation>Scheen AJ. Cardiovascular effects of dipeptidyl peptidase-4 inhibitors: from risk factors to clinical outcomes. Postgrad Med. 2013;125(3):7–20. doi: 10.3810/pgm.2013.05.2659 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.3810/pgm.2013.05.2659</ArticleId>
            <ArticleId IdType="pubmed">23748503</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jose T, Inzucchi SE. Cardiovascular effects of the DPP-4 inhibitors. Diab Vasc Dis Res. 2012;9(2):109–16. doi: 10.1177/1479164111436236
</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1479164111436236</ArticleId>
            <ArticleId IdType="pubmed">22337893</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Karagiannis T, Paschos P, Paletas K, Matthews DR, Tsapas A. Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis. BMJ. 2012;344:e1369
doi: 10.1136/bmj.e1369 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/bmj.e1369</ArticleId>
            <ArticleId IdType="pubmed">22411919</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>US Food and Drug Administration. FDA drug safety communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015 [cited 2016 Aug 17]. http://www.fda.gov/Drugs/DrugSafety/ucm459579</Citation>
        </Reference>
        <Reference>
          <Citation>Wang T, Wang F, Gou Z, Tang H, Li C, Shi L, et al.
Using real-world data to evaluate the association of incretin-based therapies with risk of acute pancreatitis: a meta-analysis of 1,324,515 patients from observational studies. Diabetes Obes Metab. 2015;17(1):32–41. doi: 10.1111/dom.12386 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.12386</ArticleId>
            <ArticleId IdType="pubmed">25200423</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Monami M, Dicembrini I, Mannucci E. Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2014;16(1):48–56. doi: 10.1111/dom.12176 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/dom.12176</ArticleId>
            <ArticleId IdType="pubmed">23837679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Giorda CB, Sacerdote C, Nada E, Marafetti L, Baldi I, Gnavi R. Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies. Endocrine. 2015;48(2):461–71. doi: 10.1007/s12020-014-0386-8 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12020-014-0386-8</ArticleId>
            <ArticleId IdType="pubmed">25146552</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yang W, Cai X, Han X, Ji L. DPP-4 inhibitors and risk of infections: a meta-analysis of randomized controlled trials. Diabetes Metab Res Rev.2016;32(4):391–404. doi: 10.1002/dmrr.2723 .</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/dmrr.2723</ArticleId>
            <ArticleId IdType="pubmed">26417956</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
